Upgrade to full year 2024 guidance underpinned by strong underlying growth momentum AstraZeneca: Revenue and EPS summary Financial performance for 9M 2024 (Growth numbers at constant exchange rates) ...
Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the research. That's according to company-sponsored studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback